SCHEMBL903435

SCHEMBL903435

CC(=O)c1ccc(Oc2ccc(C)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.83
HPGD P15428 3/20 0.83
RAB9A P51151 2/20 0.83
MMP13 P45452 2/20 0.63
MAOB P27338 1/20 0.62
SMN1; SMN2 Q16637 3/20 0.59
NPC1 O15118 1/20 0.59
MAPK1 P28482 1/20 0.59
STAT3 P40763 1/20 0.59
STAT1 P42224 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
LMNA P02545 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
ESRRA P11474 1/20 0.53
GAA P10253 1/20 0.52
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 1/20 0.50
PARP15 Q460N3 1/20 0.50
PARP14 Q460N5 1/20 0.50
PARP10 Q53GL7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9999838 1.00 MAPT (0.83) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL10014131 0.94 HPGD (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL10014134 0.94 MAPT (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL16995927 0.94 HPGD (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL12062003 0.94 HPGD (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL24380498 0.94 MAPT (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL9999840 0.94 HPGD (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL21935265 0.94 MAPT (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL22929838 0.94 MAPT (0.73) MAPTHPGDRAB9AMMP13MAOB
SCHEMBL19413155 0.94 MAPT (0.73) MAPTHPGDRAB9AMMP13MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 US claimed
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 US disclosed
CN-119470907-A Application of glyoxal-based compound in preparation of probe 深圳湾实验室 2025-02-18 CN disclosed
US-12017972-B2 All-aromatic liquid-crystalline homo-polyimides with aromatic endgroups and crosslinked products therefrom THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2024-06-25 US disclosed
US-20230374237-A1 METHOD FOR IMPREGNATING REINFORCING FIBRES WITH POLYARYLETHERKETONES AND SEMI-PRODUCTS OBTAINED THEREFROM ARKEMA FRANCE (FR) 2023-11-23 US disclosed
US-11781017-B2 Blends of polyaryletherketones having improved impact-resistance, elongation at break and flexibility ARKEMA FRANCE (FR) 2023-10-10 US disclosed
US-11746188-B2 Poly(aryl-ether-ketone) (PAEK) powder suitable for multiple use in sintering methods ARKEMA FRANCE (FR) 2023-09-05 US disclosed
US-11697718-B2 Method for impregnating reinforcing fibres with polyaryletherketones and semi-products obtained therefrom ARKEMA FRANCE (FR) 2023-07-11 US disclosed
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY Xeniopro GmbH (DE) 2023-05-11 US disclosed
CN-116018138-A Substituted 1H-imidazo [1,2-b ] pyrazole-3-carboxamides as inhibitors of brunauer tyrosine kinase 河南知微生物医药有限公司 2023-04-25 CN disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070164466-A1 Method for producing filler-containing foam slabs BASF AKTIENGESELLSCHAFT (DE) 2007-07-19 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed
WO-2007053574-A2 COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 WO disclosed
US-7189782-B2 Thermoplastic film, thermoplastic resin composition, and phyllosilicate TEIJIN LIMITED (JP) 2007-03-13 US disclosed
US-7189782-B2 Thermoplastic film, thermoplastic resin composition, and phyllosilicate TEIJIN LIMITED (JP) 2007-03-13 US disclosed
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity BAYER HEALTHCARE LLC 2007-01-25 US disclosed
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity BAYER HEALTHCARE LLC 2007-01-25 US disclosed
US-4536517-A ANTIDIABETIC, ANTILIPEMIC AGENTS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity FLT4, FLT1, FLT3 MAPT 2377/4885HPGD 1866/4885RAB9A 2233/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF MAPT 3056/4885HPGD 2117/4885RAB9A 1346/4885
US-20250368595-A1 NOVEL MOLECULES MUSK, IKZF3, TYR MAPT 3885/4885HPGD 2438/4885RAB9A 2783/4885
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY AHR, MUSK, TYR MAPT 4044/4885HPGD 1353/4885RAB9A 2351/4885
US-12017972-B2 All-aromatic liquid-crystalline homo-polyimides with aromatic endgroups and crosslinked products therefrom TPR, AS3MT, ASF1A MAPT 231/4885HPGD 3121/4885RAB9A 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.